Our characterization of the recently discovered histone methyltransferase KMT9 as a prominent regulator of lung cancer cell survival and proliferation paves the way for KMT9 inhibitors to be evaluated as a highly needed additional treatment option in multimodal lung cancer therapy. The gene discussed is PRDM9; the disease is lung carcinoma.